Andrew Wong | Senior Advisor to the Board
Walvax

Andrew Wong is a highly experienced professional with a strong background in biotech, vaccine develop- ment, and business management. Before taking on this advisory role, he was the General Manager of Shanghai Wotai Biotechnology Co., Ltd. from 2019, where he led a global team of over 50 professionals. His team was responsible for global vaccine registration, sales, marketing, technology transfer, and business development. Under his leadership, the team became one of China's leading vaccine export groups, expand- ing into 21 foreign markets such as Egypt, Morocco, Indonesia, and Thailand. Andrew's tenure at Walvax also includes an eight-year stint as Vice President of Corporate Strategy and Business Development at Shanghai Zerun Biotechnology Co., Ltd. Additionally, he was instrumental in secur- ing R&D grants for Covid-19 vaccines, totaling $26 million from the Gates Foundation and the Coalition for Epidemic Preparedness Innovations. Andrew's academic background includes training in medicine and immunology at West China Medical Uni- versity, molecular biology at the University of Manitoba, and an MBA from UCLA Anderson School of Man- agement. His 30-year career includes about 12 years of experience at Amgen Inc., where he contributed to the development of recombinant antibody therapeutics and anticancer drugs. With his extensive experience in biotech, vaccine research, and global business development.